The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review

1.

Center for Behavioral Health Statistics and Quality. 2019 National survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2020.

Google Scholar 

2.

Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202–7.

PubMed  PubMed Central  Article  Google Scholar 

3.

Centers for Disease Control and Prevention Health Alert Network. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. 2020. https://emergency.cdc.gov/han/2020/han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC_511-DM44961. Accessed 12 Jan 2020.

4.

Ahmad FBRL, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2021. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed 17 Mar 2021.

5.

Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176.

CAS  PubMed  PubMed Central  Article  Google Scholar 

6.

Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA. 2020;324(16):1673–4.

CAS  PubMed  PubMed Central  Article  Google Scholar 

7.

American Medical Association Advocacy Resource Center. Issue brief: reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic. 2020. https://www.ama-assn.org/system/files/2020-10/issue-brief-increases-in-opioid-related-overdose.pdf. Accessed 20 Oct 2020.

8.

Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.

Article  Google Scholar 

9.

Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiat. 2019;76(2):208–16.

Article  Google Scholar 

10.

Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Jones A, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298–308.

PubMed  Article  PubMed Central  Google Scholar 

11.

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.

PubMed  Article  PubMed Central  Google Scholar 

12.

Krawczyk N, Mojtabai R, Stuart EA, Fingerhood M, Agus D, Lyons BC, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683–94.

PubMed  PubMed Central  Article  Google Scholar 

13.

Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, et al. Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus. 2020;41(3):275–82.

PubMed  PubMed Central  Article  Google Scholar 

14.

Campbell CI, Saxon AJ, Boudreau DM, Wartko PD, Bobb JF, Lee AK, et al. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addict Sci Clin Pract. 2021;16(1):9.

PubMed  PubMed Central  Article  Google Scholar 

15.

Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abus. 2020;41(3):356–64.

PubMed  Article  PubMed Central  Google Scholar 

16.

Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244–50.

PubMed  PubMed Central  Article  Google Scholar 

17.

Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14–20.

PubMed  Article  PubMed Central  Google Scholar 

18.

Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. Addiction. 2020;115(2):347–53.

PubMed  Article  PubMed Central  Google Scholar 

19.

Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of “twin epidemics”: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:107592.

PubMed  PubMed Central  Article  Google Scholar 

20.

United Nations Office of Drugs and Crime. World Drug Report 2020. 2020. https://wdr.unodc.org/wdr2020/index.html. Accessed 8 Mar 2021.

21.

Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull. 2008;134(2):301–10.

PubMed  Article  PubMed Central  Google Scholar 

22.

Blondino CT, Gormley MA, Taylor DDH, Lowery E, Clifford JS, Burkart B, et al. The influence of co-occurring substance use on the effectiveness of opiate treatment programs according to intervention type. Epidemiol Rev. 2020;42(1):57–78.

PubMed  Article  PubMed Central  Google Scholar 

23.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

PubMed  PubMed Central  Article  Google Scholar 

24.

Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427–37.

PubMed  Article  PubMed Central  Google Scholar 

25.

Veritas Health Innovation. Covidence systematic review software. Melbourne: Veritas Health Innovation; 2017.

Google Scholar 

26.

Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360–3.

PubMed  PubMed Central  Google Scholar 

27.

Shiner B, Leonard Westgate C, Bernardy NC, Schnurr PP, Watts BV. Trends in opioid use disorder diagnoses and medication treatment among veterans with posttraumatic stress disorder. J Dual Diagn. 2017;13(3):201–12.

PubMed  PubMed Central  Article  Google Scholar 

28.

Rhee TG, Rosenheck RA. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Addiction. 2019;114(11):1992–9.

PubMed  PubMed Central  Article  Google Scholar 

29.

Michel L, Des Jarlais DC, Duong TH, Khuat THO, Pham MK, Peries M, et al. Intravenous heroin use in Haiphong, Vietnam: need for comprehensive care including methamphetamine use-related interventions. Drug Alcohol Depend. 2017;179:198–204.

CAS  PubMed  PubMed Central  Article  Google Scholar 

30.

Deck D, Carlson MJ. Access to publicly funded methadone maintenance treatment in two western states. J Behav Health Serv Res. 2004;31(2):164–77.

PubMed  Article  PubMed Central  Google Scholar 

31.

Fairbairn N, Hayashi K, Kaplan K, Suwannawong P, Qi J, Wood E, et al. Factors associated with methadone treatment among injection drug users in Bangkok. Thailand J Subst Abuse Treat. 2012;43(1):108–13.

PubMed  Article  PubMed Central  Google Scholar 

32.

Gjersing L, Bretteville-Jensen AL. Is opioid substitution treatment beneficial if injecting behaviour continues? Drug Alcohol Depend. 2013;133(1):121–6.

PubMed  Article  PubMed Central  Google Scholar 

33.

Daniulaityte R, Silverstein SM, Crawford TN, Martins SS, Zule W, Zaragoza AJ, et al. Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern US city. Subst Use Misuse. 2020;55(11):1781–9.

PubMed  PubMed Central  Article  Google Scholar 

34.

Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–6.

PubMed  Article  PubMed Central  Google Scholar 

35.

Hall MT, Wilfong J, Huebner RA, Posze L, Willauer T. Medication-assisted treatment improves child permanency outcomes for opioid-using families in the child welfare system. J Subst Abuse Treat. 2016;71:63–7.

PubMed  Article  PubMed Central  Google Scholar 

36.

Pettes T, Wood E, Guillemi S, Lai C, Montaner J, Kerr T. Methadone use among HIV-positive injection drug users in a Canadian setting. J Subst Abuse Treat. 2010;39(2):174–9.

PubMed  PubMed Central  Article  Google Scholar 

37.

Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus. 2020;41(1):110–20.

PubMed  Article  PubMed Central  Google Scholar 

38.

Thirion X, Micallef J, Barrau K, Djezzar S, Lambert H, Sanmarco JL, et al. Recent evolution in opiate dependence in France during generalisation of maintenance treatments. Drug Alcohol Depend. 2001;61(3):281–5.

CAS  PubMed  Article  PubMed Central  Google Scholar 

39.

Tsui JI, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80–5.

PubMed  Article  PubMed Central  Google Scholar 

40.

Skeie I, Brekke M, Clausen T, Gossop M, Lindbaek M, Reinertsen E, et al. Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study. Eur Addict Res. 2013;19(4):194–201.

CAS  PubMed  Article  PubMed Central  Google Scholar 

41.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.

PubMed  Article  PubMed Central 

留言 (0)

沒有登入
gif